Development of safe and immunogenic reassortant viruses ...Development of safe and immunogenic...
Transcript of Development of safe and immunogenic reassortant viruses ...Development of safe and immunogenic...
![Page 1: Development of safe and immunogenic reassortant viruses ...Development of safe and immunogenic reassortant viruses with 5:3 genotype for live attenuated influenza vaccine Irina Isakova-Sivak,](https://reader036.fdocuments.in/reader036/viewer/2022081403/60ac1e9467589e1b8b67f601/html5/thumbnails/1.jpg)
Development of safe and immunogenic reassortant viruses with 5:3 genotype for live attenuated influenza vaccine
Irina Isakova-Sivak, PhD
Institute of Experimental Medicine,
Saint Petersburg, Russia
The First WHO Integrated Meeting on Development and Clinical Trials of Influenza Vaccines that Induce Broadly Protective and Long-Lasting Immune Responses 24-26
January 2013, Hong Kong Baptist University, Hong Kong SAR, China 1 of 16
![Page 2: Development of safe and immunogenic reassortant viruses ...Development of safe and immunogenic reassortant viruses with 5:3 genotype for live attenuated influenza vaccine Irina Isakova-Sivak,](https://reader036.fdocuments.in/reader036/viewer/2022081403/60ac1e9467589e1b8b67f601/html5/thumbnails/2.jpg)
Reassortant LAIV in Russia
> 30 years on the Market;
> 100 million doses produced;
Effectiveness of LAIV for adults (summary from 126 trials : 500 to 45,000
adults per trial; total > 500,000 adults):
Effectiveness was confirmed for each trial.
Mean effectiveness for 126 trials was 1.80 (= 45%).
Index of effectiveness was 1.5 (= 33%), even when epidemics were
caused by new antigenic variants not presented in LAIV.
Nevertheless, new approaches to improve LAIV immunogenicity and
effectiveness are of great interest 2 of 16
![Page 3: Development of safe and immunogenic reassortant viruses ...Development of safe and immunogenic reassortant viruses with 5:3 genotype for live attenuated influenza vaccine Irina Isakova-Sivak,](https://reader036.fdocuments.in/reader036/viewer/2022081403/60ac1e9467589e1b8b67f601/html5/thumbnails/3.jpg)
PB1
PA
HA
NP
NA
M
PB2
NS
PB1
PA
HA
NP
NA
M
PB2
NS
Wild-type virus Master Donor Virus
LAIV 6:2 reassortant
Reassortant LAIV
5:3? 3 of 16
![Page 4: Development of safe and immunogenic reassortant viruses ...Development of safe and immunogenic reassortant viruses with 5:3 genotype for live attenuated influenza vaccine Irina Isakova-Sivak,](https://reader036.fdocuments.in/reader036/viewer/2022081403/60ac1e9467589e1b8b67f601/html5/thumbnails/4.jpg)
Which wt internal gene would be advantageous over ca and can be included into LAIV?
PB1
PA
NP
M
PB2
NS
Retain attenuated and high-growth phenotype of LAIV;
Improve immunogenicity and cross-protection.
?
?
?
?
?
?
4 of 16
![Page 5: Development of safe and immunogenic reassortant viruses ...Development of safe and immunogenic reassortant viruses with 5:3 genotype for live attenuated influenza vaccine Irina Isakova-Sivak,](https://reader036.fdocuments.in/reader036/viewer/2022081403/60ac1e9467589e1b8b67f601/html5/thumbnails/5.jpg)
Mutations in internal genes of MDV A/Leningrad/134/17/57 (H2N2)
PB1
PA
NP
M
PB2
NS
Master Donor Virus A/Leningrad/134/17/57 (H2N2)
Val-478-Leu
Unique mutations for MDV
Lys-265-Asn; Val-591-Ile
Leu-28-Pro; Val-341-Leu
none (egg-grown); Asn-492-Ser (MDCK-grown)
Ile-15-Val (M1); Phe-144-Leu (M1)
Met-100-Ile (NS2)
5 of 16
![Page 6: Development of safe and immunogenic reassortant viruses ...Development of safe and immunogenic reassortant viruses with 5:3 genotype for live attenuated influenza vaccine Irina Isakova-Sivak,](https://reader036.fdocuments.in/reader036/viewer/2022081403/60ac1e9467589e1b8b67f601/html5/thumbnails/6.jpg)
PB2 gene
Ts phenotype correlates with LAIV attenuation
Can NOT be replaced by wt 6 of 16
![Page 7: Development of safe and immunogenic reassortant viruses ...Development of safe and immunogenic reassortant viruses with 5:3 genotype for live attenuated influenza vaccine Irina Isakova-Sivak,](https://reader036.fdocuments.in/reader036/viewer/2022081403/60ac1e9467589e1b8b67f601/html5/thumbnails/7.jpg)
PB1 gene
Can NOT be replaced by wt 7 of 16
![Page 8: Development of safe and immunogenic reassortant viruses ...Development of safe and immunogenic reassortant viruses with 5:3 genotype for live attenuated influenza vaccine Irina Isakova-Sivak,](https://reader036.fdocuments.in/reader036/viewer/2022081403/60ac1e9467589e1b8b67f601/html5/thumbnails/8.jpg)
PB2+PB1 genes
PB2 and PB1 genes are crucial for LAIV ts phenotype (i.e. attenuation) 8 of 16
![Page 9: Development of safe and immunogenic reassortant viruses ...Development of safe and immunogenic reassortant viruses with 5:3 genotype for live attenuated influenza vaccine Irina Isakova-Sivak,](https://reader036.fdocuments.in/reader036/viewer/2022081403/60ac1e9467589e1b8b67f601/html5/thumbnails/9.jpg)
0
1
2
3
4
5
6
7
8
9
10
caLen-rg Len-ca wtLen-rg Len-wt caPB2 caPB1 caPA caNP caM caNS
log
pfu
/ml
Viruses (Parents and Mutants)
Plaque Assay Titers at 33oC, 37oC and 38oC (SGR)
33oC
37oC
38oC
PA gene
PA gene plays role in LAIV high-growth phenotype
Growth characteristics of mutant viruses
9 of 16
![Page 10: Development of safe and immunogenic reassortant viruses ...Development of safe and immunogenic reassortant viruses with 5:3 genotype for live attenuated influenza vaccine Irina Isakova-Sivak,](https://reader036.fdocuments.in/reader036/viewer/2022081403/60ac1e9467589e1b8b67f601/html5/thumbnails/10.jpg)
Klimov et al. (2001) In: Options for the Control of Influenza IV.
PA gene is responsible for LAIV ca phenotype (important for replication in URT, i.e. for local immune response)
Can NOT be replaced by wt
PA gene Virus reproduction at low temperature (25-26oC)
10 of 16
![Page 11: Development of safe and immunogenic reassortant viruses ...Development of safe and immunogenic reassortant viruses with 5:3 genotype for live attenuated influenza vaccine Irina Isakova-Sivak,](https://reader036.fdocuments.in/reader036/viewer/2022081403/60ac1e9467589e1b8b67f601/html5/thumbnails/11.jpg)
NS gene
Better not to replaced by wt
Minor effect on LAIV ts phenotype
11 of 16
![Page 12: Development of safe and immunogenic reassortant viruses ...Development of safe and immunogenic reassortant viruses with 5:3 genotype for live attenuated influenza vaccine Irina Isakova-Sivak,](https://reader036.fdocuments.in/reader036/viewer/2022081403/60ac1e9467589e1b8b67f601/html5/thumbnails/12.jpg)
0
1
2
3
4
5
6
7
8
9
10
caLen-rg Len-ca wtLen-rg Len-wt caPB2 caPB1 caPA caNP caM caNS
log
pfu
/ml
Viruses (Parents and Mutants)
Plaque Assay Titers at 33oC, 37oC and 38oC (SGR)
33oC
37oC
38oC
M gene
M gene plays role in LAIV high-growth phenotype
Growth characteristics of mutant viruses
May be replaced by wt if it doesn’t alter high-growth phenotype 12 of 16
![Page 13: Development of safe and immunogenic reassortant viruses ...Development of safe and immunogenic reassortant viruses with 5:3 genotype for live attenuated influenza vaccine Irina Isakova-Sivak,](https://reader036.fdocuments.in/reader036/viewer/2022081403/60ac1e9467589e1b8b67f601/html5/thumbnails/13.jpg)
NP gene
Can be replaced by wt 13 of 16
![Page 14: Development of safe and immunogenic reassortant viruses ...Development of safe and immunogenic reassortant viruses with 5:3 genotype for live attenuated influenza vaccine Irina Isakova-Sivak,](https://reader036.fdocuments.in/reader036/viewer/2022081403/60ac1e9467589e1b8b67f601/html5/thumbnails/14.jpg)
NP gene – major target for CTL response
CTLs targeted to some NP epitopes of Len/17 MDV do not
recognize NP of currently circulated influenza A viruses
Inclusion of NP from currently circulated influenza A viruses into LAIV formulation would
bring advantages in terms of CTL response
wt NP is the best candidate for inclusion into LAIV 5:3
reassortants
Len/17
Len/17
Len/17
Len/17
Len/17
14 of 16
![Page 15: Development of safe and immunogenic reassortant viruses ...Development of safe and immunogenic reassortant viruses with 5:3 genotype for live attenuated influenza vaccine Irina Isakova-Sivak,](https://reader036.fdocuments.in/reader036/viewer/2022081403/60ac1e9467589e1b8b67f601/html5/thumbnails/15.jpg)
Reassortants Wild-type virus
Genes from
wt virus
Age No
Reactogenicity Immunogenicicty
(seronegaive)
Temperature (%) %≥4-fold rise of Ab titer
37.1-37.5 ≥37.6-38.5 1st dose 2nd dose
A/9/30/37/88 (H3N2)
A/Leningrad/37/88 (H3N2)
HA, NA, NP
Adults (≥18) (clinic)
20 0 0 50.0 55.0
Adults (≥18) 80 0 0 50.0 60.0
Children 116 5 (4.3) 0 60.0 ND
A/Leningrad/92/89 (H1N1), R-1 A/Leningrad/92/89
(H1N1)
HA, NA, NP
Adults (≥18) 20 0 0 55.5 61.1
A/Leningrad/92/89 (H1N1), R-5
HA, NA, NP
Adults (≥18) 20 3 (15) 0 61.1 66.6
47/25/1 A(H1N1)
A/Brazil/11/79 (H1N1)
HA, NA, PA
Children 7-14 334 20 (3.4)
1 (0.6) 48.1 60.0
Children 3-6 262 2 (1.54) 48.1 59.4
47/Ph A(H3N2) A/Philippine/2/87
(H3N2) HA, NA,
PB2
Children 7-14 51 2 (3.9) 0 ND 60.0
Children 3-6 53 12 (22.6) 0 ND 48.5
Retrospective analysis of 5:3 LAIVs
All 5:3 LAIVs were safe and immunogenic 15 of 16
![Page 16: Development of safe and immunogenic reassortant viruses ...Development of safe and immunogenic reassortant viruses with 5:3 genotype for live attenuated influenza vaccine Irina Isakova-Sivak,](https://reader036.fdocuments.in/reader036/viewer/2022081403/60ac1e9467589e1b8b67f601/html5/thumbnails/16.jpg)
Summary There is a possibility of modifying LAIV genome composition by
including one additional gene from wild-type parental virus;
Polymerase genes (PB2, PB1 and PA) and NS genes of MDV A/Leningrad/134/17/57 (H2N2) can not be replaced due to their impact on LAIV ts/ca and attenuated phenotype;
In some cases M gene of MDV can be replaced by one of wild-type virus (if it doesn’t alter high-growth properties of LAIV strain);
Wild-type NP gene is the best candidate for inclusion into LAIV 5:3 reassortants due to its advantages in terms of cross-reactive CD8+ CTL response;
A pair of related LAIV reassortants with 6:2 and 5:3 genome compositions (with wt NP gene) will be evaluated for the induction of cross-reactive CD8+ CTL response.
16 of 16
![Page 17: Development of safe and immunogenic reassortant viruses ...Development of safe and immunogenic reassortant viruses with 5:3 genotype for live attenuated influenza vaccine Irina Isakova-Sivak,](https://reader036.fdocuments.in/reader036/viewer/2022081403/60ac1e9467589e1b8b67f601/html5/thumbnails/17.jpg)
Acknowledgements
• Professor L. G. Rudenko (Head of Department of Virology, IEM, St.Petersburg, Russia);
• R. O. Donis, L.-M. Chen, A.I. Klimov (CDC, Atlanta, USA);
• Staff of Department of Virology, IEM;
• WHO